Reuters Events and GRAIL Publish Whitepaper on Multi-Cancer Early Detection Implementation in Health Systems
January 17, 2023

Jan. 17, 2022 – A new whitepaper by Reuters Events and GRAIL highlights four health systems leading the way in implementing multi-cancer early detection (MCED) screening.

The whitepaper – titled Multi-Cancer Early Detection for Health Systems: Four Adoption Models – featured expert insights from early adopters including Ochsner Health; HCA Healthcare and Sarah Cannon; Providence; and the Veterans Health Administration. Each of the health systems introduced the Galleri MCED test into their practices as part of comprehensive patient care.

The paper describes how the four health systems implemented similar strategies for successfully integrating the Galleri test within their organizations. Their approaches helped define a replicable model that includes making the case for MCED internally, investing in the systems to support it, and working with physicians and patients to help them understand it.

“We were excited to partner with Reuters Events to showcase our health system partners who are leading the way in successfully implementing MCED and share their insights into how other organizations can do the same,” said Bob Ragusa, chief executive officer at GRAIL. “MCED has the potential to transform cancer care, and we hope this report helps build a roadmap for a future where it is effectively integrated into mainstream care.”

The whitepaper was produced in conjunction with the Reuters Events: Value-Based Health 2023 event. It can be accessed here: https://bit.ly/3Cta7qi.

 

###

 

About Galleri®

The earlier that cancer is detected, the higher the chance of successful outcomes. The Galleri multi-cancer early detection test can detect a shared cancer signal across more than 50 types of cancer, as defined by the American Joint Committee on Cancer Staging Manual, through a routine blood draw. When a cancer signal is detected, the Galleri test predicts the cancer signal origin, or where the cancer is located in the body, to help guide the next steps to diagnosis. The Galleri test requires a prescription from a licensed health care provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. It is intended for use in people with an elevated risk of cancer, such as those aged 50 or older.

For more information about Galleri, visit galleri.com.

 

Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “Cancer Signal Not Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

 

Laboratory/Test Information
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the U.S. Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.